Hello JITC Readers,
Welcome to the latest edition of the JITC Digest. This month I’m excited to share our special feature, spotlighting JITC’s newest review series, “Liquid Biopsies Coming of Age: Biology, Emerging Technologies, and Clinical Translation.” Our first two reviews and their companion viewpoint letters have already published, and be sure to check the collections page throughout 2023 for additional articles on this exciting and emerging frontier.
Our article highlights this month feature other exciting frontiers for the immunotherapy field including epigenetic modulation and microbial influences on anti-tumor immunity.
Lauren M Perry and colleagues describe the presence of an intratumoral microbiome and virome in soft tissue sarcoma as well as associations between intratumoral viruses, natural killer cell infiltration, and oncologic outcomes.
Rationale for combination of epigenetic modulation with macrophage-targeting therapies for the treatment of MYC-driven medulloblastoma is provided by Viktoria Marquardt and colleagues.
Two pathways for T cell-induced secretion of the TIM-3 and VISTA ligand galectin-9 from solid tumors are revealed by Stephanie Schlichtner et al.
And finally, Jelmer H van Puffelen and colleagues show that intravesical Bacillus Calmette–Guérin causes epigenetic, transcriptomic, and functional changes in myeloid cells consistent with trained immunity, which may protect patients undergoing treatment for non-muscle invasive bladder cancer from respiratory infections.
Best,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
No comments:
Post a Comment